


Product Name : CDK inhibitor E9
Cat. No. : PC-63235
CAS No. : 2020052-55-3
Molecular Formula : C₂₄H₃₀N₆O₂
Molecular Weight : 434.544
Target : Cyclin-dependent Kinase (CDK)
Solubility : 10 mM in DMSO



Biological Activity

CDK inhibitor E9 is a novel CDK inhibitor that can overcome ABC-mediated resistance of THZ1, functions as a potent, non-covalent inhibitor of **CDK9** and a covalent inhibitor of **CDK12**.

CDK inhibitor E9 does not serve as a substrate for either ABCB1 or ABCG2, while avoiding ABC transporter-mediated efflux. CDK inhibitor E9 decreases the phosphorylated and total RNAPII in THZ1R NB and lung cancer cells (IC₅₀=8-40 nM), accompanied by decreased MYC and MCL1 expression, exerts its cytotoxic effects through covalent modification of cysteine 1039 of CDK12.

References

Gao Y, et al. *Cell Chem Biol.* 2018 Feb 15;25(2):135-142.e5.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com